The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.' ...

Discover how peptides are transforming medical treatments, metabolic conditions and more with fewer side effects than ...

AM Best, a global credit rating agency focused on the insurance industry, has released its Annual Review & Preview Best's ...

This link in the pharma supply chain is undergoing a major transformation propelled by technological advancements, regulatory ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

The farnesoid X receptor (FXR) is a bile acid nuclear receptor that plays a crucial role in regulating bile acid and sterol metabolism.

In organoid and target selectivity experiments, DC646 effectively reversed the expression of GW4064-induced FXR target gene small heterodimer partner (Shp) in an FXR-dependent manner without ...

The study found that individuals who have at least one inactive copy of the GPR75 gene have lower body mass ... its large-molecule GLP-1/glucagon dual agonist cotadutide which has reached mid ...